Hematology, Blood and Marrow Transplant, and Cellular Therapy

Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC)

Our blood disorder specialists offer leading-edge therapies and comprehensive support throughout your journey.

On this page

Why choose UCSF Health for blood disorder and blood cancer treatment?

At the UCSF Health Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program, our experts provide lifesaving treatments and long-term management for malignant (cancerous) and benign (noncancerous) blood disorders.

A collaborative team of hematologists, hematologist-oncologists, immunologists and infectious disease specialists work together to plan your treatment. Nurse practitioners and social workers support your follow-up care to prevent complications and help you feel as comfortable as possible.

Our areas of expertise in blood cancers and other blood disorders

UCSF Health is home to a diverse and growing team of blood disorder specialists. The scope of our program means we have doctors with in-depth expertise in leukemia, lymphoma, myeloma, anemias, and bleeding and clotting disorders. They offer highly specialized care at every stage, from diagnosis through treatment and beyond.

We also offer programs dedicated to specific diseases, including hemophilia treatment and cutaneous lymphoma. Additionally, our specialists have experience managing blood diseases and immune disorders that affect blood cells, such as:

  • Hemophagocytic lymphohistiocytosis (HLH)

  • HIV-associated lymphoma

  • Lupus

  • Multiple sclerosis (MS)

Advanced diagnostics and second opinions for blood disorders

Patients and physicians throughout the country turn to UCSF Health for our ability to provide accurate and timely diagnoses for blood disorders. Our radiologists and pathologists, who evaluate imaging scans and tissue samples, have specialized expertise in blood and bone marrow diseases. Additionally, we use sophisticated genomic testing and molecular imaging to evaluate and stage blood cancers. These leading-edge techniques allow us to personalize your treatment strategy and better assess the effectiveness of treatment.

Our treatments for blood cancers and other blood disorders

Experts in our HBC program draw on many different treatment options to individualize your care plan. You may receive medication, chemotherapy, radiation therapy or blood transfusions, or a combination of these therapies, depending on your specific needs. We also specialize in advanced treatments for blood cancers that haven't responded to standard treatments or have returned after treatment. These may include cellular therapies, such as stem cell transplantation or CAR T-cell therapy.

Blood and bone marrow transplantation

For decades, UCSF Health has pioneered advances in stem cell transplantation. Stem cell transplantation (also called bone marrow transplantation) replaces damaged blood stem cells or bone marrow cells with healthy cells.

The goal is to stimulate your bone marrow to make new blood cells. Blood stem cells can develop into all types of blood cells, including red blood cells, white blood cells and platelets. Most people have chemotherapy and radiation therapy before their transplant to destroy cancer cells and help new stem cells grow.

We offer a range of transplant approaches, including:

  • Allogeneic transplant, using stem cells from a donor

  • Autologous transplant, using your own stem cells

  • Non-myeloablative (reduced-intensity) transplant, using a lower dose of chemotherapy and no radiation (an option for people who are older or aren't healthy enough for a standard transplant)

CAR T-cell therapy and immunotherapies for blood cancer

Immunotherapies are drugs that harness your body's immune system to fight cancer. UCSF Health is globally recognized for our groundbreaking work in cell-based immunotherapy. Our researchers and physicians developed the first FDA-approved checkpoint inhibitor more than a decade ago — a type of immunotherapy now used worldwide.

We continue to lead the field by actively engaging in CAR T-cell treatment and research. CAR T-cell therapy collects immune cells from your body and genetically modifies them in a lab. The new cells are reintroduced into your body, where they can identify and attack cancer cells. CAR T-cell therapy may benefit people with certain types of leukemia, lymphoma or myeloma.

UCSF Health researchers are actively investigating new uses for CAR T-cell therapy, as well as other emerging treatments that directly target cancer cells.

Locations

    View all

    Providers

    Excellence in patient care

    Our expertise has earned top rankings from U.S. News & World Report.
    • Best in California and No. 7 in the nation for cancer care

    • Rated high-performing hospital for leukemia, lymphoma & myeloma care

    • 220+

      blood and marrow transplants performed each year

    • This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investigate using circulating tumor DNA (ctDNA) at pre-determined time points using Foresight CLARITY LDT, an ultra-sensitive liquid biopsy platform that detects Minimal residual disease (MRD) in patients with B-cell lymphomas using the phased variant enrichment and sequencing technology (PhasEDq) to determine response to study interventions.
    • This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITYâ„¢ Investigational Use Only (IUO) MRD test, powered by PhasED-Seqâ„¢. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.
    • This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a drug called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, and delivers vedotin to kill them. Chemotherapy drugs, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving mosunetuzumab and/or polatuzumab vedotin after chemotherapy and CAR T-cell therapy may be more effective at controlling or shrinking the cancer than not giving them.
    • This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
    • The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).
    • The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are:

    Accreditations & memberships

    • FACT Logo

      Foundation for Accreditation of Cellular Therapy

      Our HBC Program is accredited by the Foundation for Accreditation of Cellular Therapy (FACT). FACT-accredited programs follow specific high-quality medical and laboratory processes when providing cellular therapies, such as bone marrow transplants.
    • National Cancer Institute

      National Cancer Institute

      The National Cancer Institute has designated UCSF Health a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.
    • Commission on Cancer

      Commission on Cancer

      UCSF Health's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.
    • National Comprehensive Cancer Network

      National Comprehensive Cancer Network

      UCSF is a member of the National Comprehensive Cancer Network, an alliance of the world's top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.

    Research initiatives

    Cancer immunotherapy

    Our providers work with cancer immunotherapy experts to provide comprehensive care for people with blood cancers.

    Advanced blood disorder care for children

    We provide advanced treatments for children with noncancerous and cancerous blood disorders, such as anemia and sickle cell disease.